Introduction
============

Infectious mononucleosis (IM) is a common disease associated with Epstein-Barr virus (EBV) infection and \~5 cases occur per 1,000 people every year ([@b1-etm-0-0-5736],[@b2-etm-0-0-5736]) The results of a survey conducted in Beijing indicated that the incidence of IM peaks among preschool children and young people aged 15--24 years old ([@b3-etm-0-0-5736]). Diagnosis of IM is generally based on identifying the triad of clinical manifestations of fever, pharyngitis and lymphadenopathy in patients, as well as a positive result following a serological test for EBV ([@b1-etm-0-0-5736],[@b2-etm-0-0-5736]). However, patients with IM also exhibit other symptoms, including headache, fatigue, exanthema, hepatomegaly and splenomegaly ([@b4-etm-0-0-5736]). The majority of patients with IM recover without complications and return to their normal activities \~2 months following disease onset ([@b1-etm-0-0-5736],[@b2-etm-0-0-5736]). However, severe complications, including upper-airway obstruction, hemolytic anemia, thrombocytopenia, hepatitis, myocarditis, splenic rupture, neurological and hematological complications may occur in certain cases ([@b1-etm-0-0-5736],[@b2-etm-0-0-5736]). The treatment for IM is generally supportive and only alleviates symptoms, as EBV cannot be cured; these treatments include glucose and sodium chloride intravenous infusion, reduced glutathione intravenous infusion, pantoprazole sodium injection, and oral loxoprofen and bicyclol tablets intake ([@b1-etm-0-0-5736],[@b2-etm-0-0-5736]). Abnormality of hepatic function is commonly encountered in IM; however, it has been demonstrated for many years that increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyl transferase (GGT) occur more frequently in IM than bilirubin abnormalities ([@b1-etm-0-0-5736]--[@b12-etm-0-0-5736]). However, the underlying reasons for these elevations remain unknown. The results of previous studies demonstrated that \>80% of patients with IM presented with abnormal transferase levels, particularly ALT, but jaundice was uncommon ([@b1-etm-0-0-5736],[@b2-etm-0-0-5736],[@b13-etm-0-0-5736]). In addition, Hu *et al* ([@b14-etm-0-0-5736]) indicated that the presence of atypical lymphocytes and transaminase may be regarded as a diagnostic marker of IM.

The aim of the current study was to analyze the associations between hepatic function parameters and IM in a comprehensive manner. The aim was to identify whether abnormal hepatic function could be indicative of IM and whether there were any significant differences between hepatic function parameters between males and females.

Patients and methods
====================

### Patients

Between December 2014 and December 2015, 95 patients (mean age, 39.36 years; 47 males and 48 females) with a confirmed diagnosis of IM were enrolled in the Department of Infectious Diseases, Tianjin Medical University General Hospital (Tianjin, China). Patients with pre-existing liver diseases, including viral hepatitis, fatty liver disease, alcoholic liver disease and medication-induced liver damage, were excluded from the current study. During the same period, a normal control cohort consisting of 95 healthy participants (mean age, 39.45 years; 47 males and 48 females) was recruited from the Health Management Department, Tianjin Medical General University. None of the healthy participants had been diagnosed with any diseases and had attended Tianjin Medical General University for an annual health checkup. The ethical, methodological and protocol aspects of the current investigation were approved by the Institutional Review Board of Tianjin Medical University General Hospital and written informed consent was provided by all participants.

### Parameter measurements

Following admittance of patients with IM to the Department of Infectious Diseases, blood tests and anthropometric measurements were conducted. For participants in the control group, blood tests and anthropometric measurements were completed during their visit to the hospital. Physical examinations included measurements of body height (BH) and body weight (BW). Subsequently, body mass index (BMI; kg/m^2^) was calculated using the following formula: BW/(BH^2^). Fasting blood tests were performed following venipuncture and the following serological parameters were measured: White blood cell (WBC), red blood cell (RBC), hemoglobin (Hg) and platelet (PLT) levels. A total of 3 ml of whole blood samples were collected and analyzed using a hemocytometer analyzer (Sysmex Corporation, Kobe, Japan). ALT, AST, GGT, total bilirubin (TB), blood urea nitrogen (BUN) and creatinine (Cr) levels were measured using the Hitachi Model 7170 analyzer (Hitachi Ltd., Tokyo, Japan). Levels of immunoglobulin (Ig)M and IgG antibodies against specific EBV antigens were measured by ELISA using three commercial kits (viral capsid antigen antibody IgM, cat. no. E170606AK; viral capsid antigen antibody IgG, cat. no. E170706BO; viral nuclear antigen antibody IgG, cat. no. E170706BR) supplied by (Euroimmun; Medizinische Labordiagnostika AG, Lübeck, Germany). Ultrasonography on neck lymph nodes and abdominal organs was performed the using PHILIPS HD11 XE (Philips, Amsterdam, The Netherlands).

### Diagnostic criteria

IM was generally diagnosed based on clinical presentations of a fever, pharyngitis, lymphadenopathy, the presence of atypical lymphocytes on a peripheral blood smear and a positive heterophile antibody test. The majority of the included patients referred to Tianjin Medical University General Hospital (Tianjin, China) were diagnosed with IM in local hospitals prior to recruitment. In order to establish definite IM diagnosis, serological testing for the identification of antibodies against specific EBV antigens was required by the aforementioned ELISA kits ([@b1-etm-0-0-5736],[@b2-etm-0-0-5736]).

### Statistical analysis

All data for males and females were analyzed separately and presented as either the mean ± standard deviation or the median (lower quartile, upper quartile). Differences of parameters between groups were measured using an independent samples T test or a Mann-Whitney test. Pearson\'s bivariate correlation analysis was performed between hepatic function indices and other variables. Receiver operating characteristic (ROC) curves were constructed and diagnostic efficacies were determined using optimal sensitivity and specificity values calculated from hepatic function indices. To compare ROC curves, a previously described protocol was used ([@b15-etm-0-0-5736]). By stratifying data with quartiles of hepatic function indices, the odds ratio (OR) for IM with a 95% confidence interval (CI) was calculated using binary logistic regression models. OR adjustments were completed by using age and BMI as covariates in a logistic regression model. The Statistical Package for Social Sciences (SPSS v17.0, Chicago, IL, USA) was used for statistical analysis and P\<0.05 was determined to indicate a significant difference.

Results
=======

### Patient clinicopathological characteristics

Parameters were compared in males and females separately ([Tables I](#tI-etm-0-0-5736){ref-type="table"} and [II](#tII-etm-0-0-5736){ref-type="table"}). In males, WBC, ALT, AST and GGT were significantly higher in patients with IM than in healthy controls ([Table I](#tI-etm-0-0-5736){ref-type="table"}). However, RBC, Hg and TB were significantly lower in males with IM compared with controls. In females, ALT, AST and GGT were significantly higher in females with IM than in controls ([Table II](#tII-etm-0-0-5736){ref-type="table"}). However, RBC, Hg, TB, BUN and Cr were significantly lower in females with IM compared with controls.

### Correlations between key variables

Correlation coefficients between hepatic function indices and other parameters were calculated in patients with IM ([Table III](#tIII-etm-0-0-5736){ref-type="table"}). In males, ALT was positively correlated with WBC, AST and GGT, whereas in females, ALT was positively correlated with AST and GGT. AST was positively correlated with WBC, ALT and GGT in males and positively correlated with ALT and GGT in females. GGT was positively correlated with WBC, ALT and AST in males and positively correlated with age, BMI, WBC, ALT and AST in females. In males, TB only exhibited a positive correlation with Hg; however in females, TB was positively correlated with RBC, Hg and Cr.

### Diagnostic or predicative values of hepatic function indices for IM

From ROC analyses, all hepatic function indices exhibited significant diagnostic or predicative values for IM ([Fig. 1](#f1-etm-0-0-5736){ref-type="fig"} and [Table IV](#tIV-etm-0-0-5736){ref-type="table"}). If ALT, AST and GGT concentrations were higher than the cut-off values of 27.5, 21.5 and 29.5 U/l in males, diagnostic accuracies of IM were 74.468, 71.277 and 75.532%, respectively. In females, the cut-off values for ALT, AST and GGT were 15.5, 17.5 and 18.0 U/l and diagnostic accuracies of IM were 67.708, 66.667 and 72.917%, respectively. If TB concentrations were lower than the cut-off values of 10.70 µmol/l in males and 7.45 µmol/l in females, diagnostic accuracies were 64.89 and 78.125%, respectively. Comparison of ROC curves in males and females did not identify any evident differences.

### Risks of IM in different hepatic function status

Binary logistic regression models were utilized to calculate the risks of IM in the males and females ([Table V](#tV-etm-0-0-5736){ref-type="table"}). For transferases, crude OR calculations were performed using the lowest quartiles as references. High transferase levels significantly increased IM risk, particularly in males. Following adjustments using age and BMI as covariates, males with high levels of transferases exhibited a much greater susceptibility to IM. Crude ORs in ALT quartile 4 were 21.667 and 10.111 for males and females, respectively; however adjusted ORs were 38.054 and 9.882, respectively (all P\<0.01). For TB, crude OR calculations were performed using the highest quartile as a reference. Lower TB levels were deemed to significantly increase the risk of IM in males and females. Adjusted OR calculations used age and BMI as covariates. Notably, females exhibited a higher risk of developing IM when they exhibited low serum TB. Crude ORs in quartile 1 were 8.229 and 8.257 for males and females, respectively; however, adjusted ORs were 8.883 and 10.048, respectively (all P\<0.01).

Discussion
==========

Worldwide, \>95% of adults are infected with EBV and in industrialized countries, it is estimated that \~50% of the population experiences primary EBV infection \<5 years old ([@b1-etm-0-0-5736]). Most people infected with EBV are either asymptomatic or exhibit mild symptoms; however, some will develop IM. Mild to moderate elevations of liver enzymes occur in 80--90% of patients with IM, however jaundice only occurs in 5% ([@b1-etm-0-0-5736]--[@b3-etm-0-0-5736],[@b13-etm-0-0-5736]). Furthermore, hepatic failure in patients with IM has been reported only occasionally ([@b16-etm-0-0-5736]--[@b18-etm-0-0-5736]). The three most clinically relevant transferases are ALT, AST and GGT, which are the primary indices of liver function ([@b19-etm-0-0-5736]). Transaminases transfer amino and keto groups between amino acids and keto acids ([@b19-etm-0-0-5736]). ALT catalyzes this interconversion between L-alanine and α-ketoglutarate on one side and pyruvate and L-glutamate on the other. AST catalyzes this interconversion between aspartate and α-ketoglutarate on one side and oxaloacetate and glutamate on the other ([@b19-etm-0-0-5736]). GGT belongs to the subclass of amino-acyltransferases, which transfer acyl groups between amino acids and peptides ([@b19-etm-0-0-5736]). GGT catalyzes the transfer from a 5-L-glutamyl-peptide and an amino acid on one side to a peptide and a 5-L-glutamyl amino acid on the other ([@b19-etm-0-0-5736]). Analysis of liver biopsies taken from patients with IM identified marked periportal lymphocytic infiltration, marked Kupffer cell activity and considerable acidophilic degeneration of individual liver cells ([@b20-etm-0-0-5736]), which may explain why transferase levels are increased in patients with IM. By contrast, patients with infectious hepatitis exhibit necrosis and inflammatory exudates ([@b21-etm-0-0-5736]). The results of the current study indicate that ALT, AST and GGT levels are significantly increased in males and females with IM compared with controls, indicating that transferase levels may be used to diagnose IM or determine IM risk. High transferase levels significantly increased the risk of IM, particularly in males.

Bilrubin is a by-product of heme degradation ([@b22-etm-0-0-5736]). The enzyme heme-oxygenase catalyzes heme and results in the formation of three products: Biliverdin, ferrous iron and carbon monoxide. Biliverdin is reduced to bilirubin by biliverdin reductase, bilirubin then binds to albumin and circulates in the blood. Bilirubin is then neutralized following its encounter with hepatocytes ([@b22-etm-0-0-5736]). The metabolic pathway that converts biliverdin, a soluble and nontoxic heme product, into bilirubin, which is insoluble and potentially toxic, has been evolutionarily conserved ([@b22-etm-0-0-5736]). It has therefore been hypothesized that bilirubin may serve an important physiological role. Previous studies have demonstrated that, although bilirubin is cytotoxic at high concentrations, at physiological concentrations bilirubin is able to scavenge free radicals and has powerful immunosuppressive effects ([@b23-etm-0-0-5736]--[@b25-etm-0-0-5736]). Indeed, the antioxidant effect of bilirubin is \~20 times more potent than that of Vitamin E, a known scavenger of free radicals ([@b26-etm-0-0-5736]).

Low serum bilirubin was identified as a strong, independent risk factor for coronary disease in 1994 ([@b27-etm-0-0-5736]) and the inverse association between bilirubin levels and coronary artery disease has been confirmed ([@b28-etm-0-0-5736],[@b29-etm-0-0-5736]). Targeting heme-oxygenase and regulating biliverdin reductase may be novel methods of treating coronary artery disease and are currently under investigation ([@b28-etm-0-0-5736],[@b29-etm-0-0-5736]). Niacin induces heme-oxygenase, which may partially explain its vascular protective properties ([@b30-etm-0-0-5736]). Bilirubin affects the immune system at physiological concentrations ([@b23-etm-0-0-5736]); for example, bilirubin inhibits the complement cascade by interrupting the binding of the C1 complex to the complement antibody ([@b31-etm-0-0-5736]). Bilirubin may also inhibit the cell-surface expression of major histocompatibility complex II molecules on antigen-presenting cells ([@b32-etm-0-0-5736]). Furthermore, following entry into a target cell, bilirubin may engage in the widespread inhibition of protein kinases ([@b33-etm-0-0-5736]). In various inflammatory and immunological disorders, including multiple sclerosis ([@b34-etm-0-0-5736]), Crohn\'s disease ([@b35-etm-0-0-5736]) and systemic lupus erythematosus ([@b36-etm-0-0-5736]), bilirubin may be depleted following completion of its functions.

One of the objectives of the current study was to investigate the association between IM and bilirubin. It has been demonstrated that oxidative stress serves a crucial role in the pathogenesis of various infections, including the hepatitis virus ([@b37-etm-0-0-5736]), respiratory viruses ([@b38-etm-0-0-5736]), human immunodeficiency virus ([@b39-etm-0-0-5736]), influenza virus ([@b40-etm-0-0-5736]), *Staphylococcus aureus* ([@b41-etm-0-0-5736]), *Helicobacter pylori* ([@b42-etm-0-0-5736]) and mycoplasma ([@b43-etm-0-0-5736]). It is hypothesized that an infection due to EBV may also cause oxidative stress, leading to the marked depletion of antioxidants, such as bilirubin. This may be the underlying mechanism explaining the decrease in bilirubin observed in patients with IM in the current study. Furthermore, the present study indicates that females with low bilirubin levels are more susceptible to developing IM than males with low bilirubin levels. Males generally exhibit much higher serum bilirubin than females ([@b44-etm-0-0-5736]) and this was confirmed in the current study. Higher bilirubin levels may confer more antioxidant protection in males, therefore females may be more susceptible to the oxidative stress caused by bilirubin depletion. Consequently, decreased bilirubin may be more predictive of IM infection in females than males.

In the present study, there were differences between males and females among indices other than liver function parameters. Cr and BUN levels, as well as WBC levels, were significantly higher in males than in females. Previous studies have demonstrated that Cr levels are equal in children; however during adolescence, Cr levels increase more in males than females ([@b45-etm-0-0-5736],[@b46-etm-0-0-5736]). In adulthood, females have lower serum Cr values than males with similar renal function ([@b47-etm-0-0-5736]). Cr and BUN induce the same effects in males and females ([@b48-etm-0-0-5736]--[@b53-etm-0-0-5736]). The results of studies investigating WBC levels are inconsistent; certain studies indicate that WBC levels are higher in males ([@b54-etm-0-0-5736],[@b55-etm-0-0-5736]), whereas others indicate that WBC levels are higher in females ([@b56-etm-0-0-5736],[@b57-etm-0-0-5736]). However, major influential factors include age and sex hormone levels; indeed, it has been suggested that WBC levels may change in females at different stages of the menstrual cycle ([@b54-etm-0-0-5736]). In addition, liver function parameters are associated with age, body fat, renal function and blood cells ([@b48-etm-0-0-5736]--[@b53-etm-0-0-5736]) and correlations between these key variables were identified in the current study.

There were several limitations of the current study. Firstly, the cross-sectional design of the current investigation meant that no causality could be determined. A prospective study should therefore be performed in the future. Secondly, a limited number of patients with IM and controls were evaluated and they were only recruited from a single center. More participants should be recruited from multiple centers in order to verify the results of the current study. Thirdly, due to budget limitations of the current study, measurements of serum parameters were based on a single determination and markers of inflammation or activities of antioxidants were not assessed. Finally, the administration of bilirubin as a possible adjuvant therapy should be investigated in the future to validate the results of the current study.

In conclusion, the results of the current study identified a positive association between transferases and IM and a negative association between TB and IM, suggesting that there is a progressive decrease of antioxidant reserves during IM. High transferase levels were suggestive of IM, particularly in males, whereas low TB was suggestive of IM, particularly in females.
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###### 

Parameter characteristics in males.

  Parameters      Patients with IM        Controls               T value/Z value
  --------------- ----------------------- ---------------------- ------------------------------------------------------
  Case no.        47                      47                     
  Age (years)     37.40±16.83             37.68±16.83            −0.080
  BMI (kg/m2)     23.58±3.02              24.74±3.50             −1.725
  WBC (×109/l)    7.17±3.81               5.93±1.49              2.085^[a](#tfn2-etm-0-0-5736){ref-type="table-fn"}^
  RBC (×1012/l)   4.46±0.51               5.19±0.38              −7.870^[b](#tfn3-etm-0-0-5736){ref-type="table-fn"}^
  Hg (g/l)        133.19±14.59            155.15±10.21           −8.453^[b](#tfn3-etm-0-0-5736){ref-type="table-fn"}^
  PLT (×109/l)    208.47±80.43            214.81±46.92           −0.467
  ALT (U/l)       50.00 (22.00, 107.00)   19.00 (14.00, 27.00)   4.411^[b](#tfn3-etm-0-0-5736){ref-type="table-fn"}^
  AST (U/l)       31.00 (19.00, 63.00)    18.00 (14.00, 22.00)   4.216^[a](#tfn2-etm-0-0-5736){ref-type="table-fn"}^
  GGT (U/l)       57.00 (25.00, 123.00)   20.00 (16.00, 29.00)   5.164^[b](#tfn3-etm-0-0-5736){ref-type="table-fn"}^
  TB (µmol/l)     9.50 (7.10, 11.90)      11.70 (9.90, 17.90)    2.934^[b](#tfn3-etm-0-0-5736){ref-type="table-fn"}^
  BUN (mmol/l)    4.10±1.74               4.56±1.22              −1.496
  Cr (µmol/l)     76.30±28.92             83.34±12.75            −1.528

Data presented as mean ± standard deviation or median (lower quartile, upper quartile).

P\<0.05

P\<0.01 (analyzed by independent sample\'s t test or Mann-Whitney test). IM, infectious mononucleosis; BMI, body mass index; WBC, white blood cell; RBC, red blood cell; Hg, hemoglobin; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; TB, total bilirubin; BUN, blood urea nitrogen; Cr, creatinine.

###### 

Parameter characteristics in females.

  Parameters      Patients with IM       Controls               T value
  --------------- ---------------------- ---------------------- ------------------------------------------------------
  Case no.        48                     48                     
  Age (years)     41.27±17.54            41.19±17.35            0.023
  BMI (kg/m2)     23.52±3.81             22.60±2.94             1.314
  WBC (×109/l)    6.29±3.62              5.17±1.54              1.975
  RBC (×1012/l)   3.93±0.43              4.44±0.27              −6.954^[a](#tfn5-etm-0-0-5736){ref-type="table-fn"}^
  Hg (g/l)        113.54±13.34           130.73±8.49            −7.530^[a](#tfn5-etm-0-0-5736){ref-type="table-fn"}^
  PLT (×109/l)    235.65±90.10           226.15±50.15           0.638
  ALT (U/l)       20.00 (12.00, 68.50)   13.00 (9.25, 15.75)    3.342^[a](#tfn5-etm-0-0-5736){ref-type="table-fn"}^
  AST (U/l)       21.50 (16.00, 49.00)   15.50 (13.00, 18.75)   4.096^[a](#tfn5-etm-0-0-5736){ref-type="table-fn"}^
  GGT (U/l)       25.50 (13.00, 49.50)   11.00 (10.00, 16.75)   4.101^[a](#tfn5-etm-0-0-5736){ref-type="table-fn"}^
  TB (µmol/l)     6.10 (4.90, 7.55)      9.70 (7.65, 12.28)     4.379^[a](#tfn5-etm-0-0-5736){ref-type="table-fn"}^
  BUN (mmol/l)    2.97±1.05              4.15±1.15              −5.242^[a](#tfn5-etm-0-0-5736){ref-type="table-fn"}^
  Cr (µmol/l)     52.13±9.46             60.77±9.59             −4.446^[a](#tfn5-etm-0-0-5736){ref-type="table-fn"}^

Data presented as mean ± standard deviation or median (lower quartile, upper quartile).

P\<0.01 (analyzed by independent sample\'s t test or Mann-Whitney test). IM, infectious mononucleosis; BMI, body mass index; WBC, white blood cell; RBC, red blood cell; Hg, hemoglobin; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; TB, total bilirubin; BUN, blood urea nitrogen; Cr, creatinine.

###### 

Pearson bivariate correlations in males and females.

        Correlation coefficients in males                      Correlation coefficients in females                                                                                                                                                                                                                                                                                                     
  ----- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------
  Age   −0.242^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.175                                                 −0.041                                                 −0.072                                                −0.132                                                 −0.079                                                 0.232^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   0.007
  BMI   0.017                                                  0.008                                                  0.047                                                  −0.011                                                −0.005                                                 0.043                                                  0.355^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^   0.122
  WBC   0.453^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    0.216^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^    0.427^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    0.090                                                 0.129                                                  0.115                                                  0.232^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.097
  RBC   −0.129                                                 −0.097                                                 −0.307^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^   0.167                                                 −0.228^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.232^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.099                                                0.243^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^
  Hg    −0.166                                                 −0.152                                                 −0.291^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^   0.235^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.134                                                 −0.149                                                 −0.047                                                0.337^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^
  PLT   −0.086                                                 −0.132                                                 −0.032                                                 0.088                                                 −0.291^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^   −0.306^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^   0.058                                                 −0.258^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^
  ALT   --                                                     0.850^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    0.672^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    0.002                                                 --                                                     0.942^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    0.403^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^   0.001
  AST   0.850^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    --                                                     0.534^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    −0.036                                                0.942^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    --                                                     0.426^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^   −0.003
  GGT   0.672^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    0.534^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    --                                                     0.080                                                 0.403^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    0.426^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^    --                                                    0.161
  TB    0.002                                                  −0.036                                                 0.080                                                  --                                                    0.001                                                  −0.003                                                 0.161                                                 --
  BUN   −0.237^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.209^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.031                                                 −0.048                                                −0.205^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.240^[a](#tfn6-etm-0-0-5736){ref-type="table-fn"}^   −0.021                                                0.195
  Cr    −0.082                                                 −0.075                                                 0.131                                                  0.127                                                 −0.084                                                 −0.101                                                 0.028                                                 0.284^[b](#tfn7-etm-0-0-5736){ref-type="table-fn"}^

P\<0.05

P\<0.01. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; TB, total bilirubin; BMI, body mass index; WBC, white blood cell; RBC, red blood cell; Hg, hemoglobin; PLT, platelet; BUN, blood urea nitrogen; Cr, creatinine.

###### 

ROC indices of hepatic parameters for diagnosing or predicting IM.

  A, Male                                                                                                                                                                 
  ---------------- ----------------------------------------------------- ------------------- --------------------- --------------------- ------------------ ------------- -------------
  ALT              0.764^[a](#tfn8-etm-0-0-5736){ref-type="table-fn"}^   27.5 U/l            72.300                76.600                74.468             75.556        73.469
  AST              0.752^[a](#tfn8-etm-0-0-5736){ref-type="table-fn"}^   21.5 U/l            70.200                72.300                71.277             71.739        70.833
  GGT              0.809^[a](#tfn8-etm-0-0-5736){ref-type="table-fn"}^   29.5 U/l            74.500                76.600                75.532             76.087        75.000
  TB               0.676^[a](#tfn8-etm-0-0-5736){ref-type="table-fn"}^   10.70 µmol/l        63.800                66.000                64.894             64.583        65.217
                                                                                                                                                                          
  **B, Female**                                                                                                                                                           
                                                                                                                                                                          
  **Parameters**   **AUC**                                               **Cut-off value**   **Sensitivity (%)**   **Specificity (%)**   **Accuracy (%)**   **PPV (%)**   **NPV (%)**
                                                                                                                                                                          
  ALT              0.698^[a](#tfn8-etm-0-0-5736){ref-type="table-fn"}^   15.5 U/l            60.400                75.000                67.708             70.732        65.455
  AST              0.742^[a](#tfn8-etm-0-0-5736){ref-type="table-fn"}^   17.5 U/l            64.600                68.700                66.667             67.391        66.000
  GGT              0.742^[a](#tfn8-etm-0-0-5736){ref-type="table-fn"}^   18.0 U/l            68.800                77.100                72.917             75.000        71.154
  TB               0.759^[a](#tfn8-etm-0-0-5736){ref-type="table-fn"}^   7.45 µmol/l         81.300                75.000                78.125             80.000        76.471

P\<0.01. ROC, receiver operating characteristic; IM, infectious mononucleosis; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; TB, total bilirubin.

###### 

IM risk according to liver parameter quartiles in the two sexes.

                     Males                    Females                                                                                                                                                                                                                                             
  ------------------ ------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------- ------------------------ ----------------------------------------------------------------------- ------------------------------------------------------------------------
  ALT (U/l)                                                                                                                                                                                                                                                                                       
    ALT Quartile 1   ALT≤15.00 (reference)                                                                                                                                                       ALT≤11.00 (reference)                                                                            
    ALT Quartile 2   15.00\<ALT≤25.00         1.238 (0.310--4.947)                                                     1.279 (0.306--5.341)                                                      11.00\<ALT≤14.00         0.674 (0.196--2.320)                                                    0.679 (0.196--2.351)
    ALT Quartile 3   25.00\<ALT≤63.00         4.875 (1.230--19.319)^[a](#tfn9-etm-0-0-5736){ref-type="table-fn"}^      7.149 (1.635--31.265)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^      14.00\<ALT≤27.50         0.935 (0.299--2.920)                                                    0.933 (0.281--3.103)
    ALT Quartile 4   ALT\>63.00               21.667 (4.154--113.020)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^   38.054 (6.241--232.038)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^    ALT\>27.50               10.111 (2.306--44.348)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^   9.882 (2.076--47.038)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^
  AST (U/l)                                                                                                                                                                                                                                                                                       
    AST Quartile 1   AST≤17.00 (reference)                                                                                                                                                       AST≤14.00 (reference)                                                                            
    AST Quartile 2   17.00\<AST≤21.00         1.813 (0.487--6.758)                                                     2.517 (0.639--9.909)                                                      14.00\<AST≤17.00         1.486 (0.386--5.722)                                                    1.462 (0.378--5.663)
    AST Quartile 3   21.00\<AST≤38.25         4.636 (1.309--16.423)^[a](#tfn9-etm-0-0-5736){ref-type="table-fn"}^      6.948 (1.783--27.072)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^      17.00\< AST≤26.00        1.878 (0.536--6.581)                                                    1.924 (0.545--6.793)
    AST Quartile 4   AST\>38.25               16.150 (3.718--70.142)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^    26.313 (5.384--128.603)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^    AST\>26.00               19.067 (3.899--93.227)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^   20.642 (3.936--108.262)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^
  GGT (U/l)                                                                                                                                                                                                                                                                                       
    GGT Quartile 1   GGT≤18.00 (reference)                                                                                                                                                       GGT≤10.00 (reference)                                                                            
    GGT Quartile 2   18.00\<GGT≤28.00         1.684 (0.427--6.642)                                                     3.074 (0.694--13.610)                                                     10.00\<GGT≤16.00         0.943 (0.253--3.509)                                                    0.977 (0.260--3.668)
    GGT Quartile 3   28.00\<GGT≤63.25         6.667 (1.690--26.298)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^     20.922 (3.910--111.945)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^    16.00\<GGT≤34.75         3.000 (0.807--11.147)                                                   3.030 (0.797--11.513)
    GGT Quartile 4   GGT\>63.25               26.667 (5.199--136.777)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^   79.281 (11.149--563.762)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^   GGT\>34.75               8.360 (1.971--35.461)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^    9.093 (1.927--42.903)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^
  TB (µmol/l)                                                                                                                                                                                                                                                                                     
    TB Quartile 1    TB≤8.250                 8.229 (2.175--31.132)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^     8.883 (2.287--34.502)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^      TB≤5.700                 8.257 (2.184--31.222)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^    10.048 (2.482--40.682)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^
    TB Quartile 2    8.250\<TB≤10.550         5.040 (1.400--18.140)^[a](#tfn9-etm-0-0-5736){ref-type="table-fn"}^      5.220 (1.402--19.436)^[a](#tfn9-etm-0-0-5736){ref-type="table-fn"}^       5.700\<TB≤7.600          9.229 (2.463--34.583)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^    10.457 (2.633--41.535)^[b](#tfn10-etm-0-0-5736){ref-type="table-fn"}^
    TB Quartile 3    10.550\<TB≤15.575        3.600 (1.007--12.865)^[a](#tfn9-etm-0-0-5736){ref-type="table-fn"}^      3.839 (1.041--14.158)^[a](#tfn9-etm-0-0-5736){ref-type="table-fn"}^       7.600\<TB≤11.650         0.578 (0.155--2.151)                                                    0.586 (0.153--2.249)
    TB Quartile 4    TB\>15.575 (reference)                                                                                                                                                      TB\>11.650 (reference)                                                                           

P\<0.05

P\<0.01.

Logistic regression model without covariates

Logistic regression model with age and BMI as covariates. IM, infectious mononucleosis; OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; TB, total bilirubin.
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